Compass Therapeutics Updates on Clinical Progress and Leadership Changes
Compass Therapeutics provided a general business update highlighting progress throughout its pipeline of clinical-stage drug candidates. The analyses of progression-free survival and overall survival remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig in patients with advanced biliary tract cancer. In the ongoing Phase 1 dose-escalation study of CTX-8371, a previously reported third response has now been confirmed in a patient with Hodgkin Lymphoma. CTX-8371 has demonstrated responses in patients with both solid tumor and hematologic malignancies. Also in the CTX-8371 Phase 1 study, the previously disclosed deep partial response in a patient with triple negative breast cancer is now durable through week 32. Initiation of a Phase 1 study of CTX-10726 is expected in Q1 2026 with initial data from this study expected in H2 2026. Compass expanded its senior leadership team with the appointment of Arjun Prasad, MBA, MPH, as Chief Commercial Officer and Cynthia Sirard, MD, as Chief Medical Officer. Data from tovecimig's Phase 2 study in patients with colorectal cancer will be presented at the 2026 ASCO GI Cancers Symposium. Estimated $209 million in cash and marketable securities as of December 31, 2025, which is expected to provide cash runway into 2028
